Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
The patient had a high-grade DCIS with necrosis, but a 0.9 DCSionRT score
Answer from: Radiation Oncologist at Community Practice
For now, I have been only omitting/discussing omission if both, clinical path and molecular test are concordant.
Sign in or Register to read more
21306
Related Questions
Is it appropriate to use bolus with hypofractionated PMRT?
Is re-excision of residual disease ever itself an indication for PMRT?
Does micropapillary subtype for a G1-2 DCIS affect your radiation treatment recommendations?
Do you recommend high ozonated oil for radiation dermatitis?
How would you approach reirradiation in a patient with a history of whole-breast RT many years ago, now with a small intermediate-grade DCIS s/p lumpectomy with an elevated DCISionRT?
What is the maximum dose that you would give to residual unresectable gross disease in the axilla in the setting of recurrent breast cancer s/p ALND?
Is FAST-Forward/ultra-hypofractionation suitable for an early-stage breast patient after a lumpectomy with oncoplastic reduction?
Does a post-surgical hematoma in the breast affect your recommendations for partial breast RT?
Under what circumstances would you pursue completion ALND in a patient with multiple positive sentinel nodes after breast-conserving surgery?
Have the 10-year results from UK FAST-Forward presented at ESTRO 2025 impacted your practice with regard to patient selection?